CA2659477A1 - Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy - Google Patents

Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy Download PDF

Info

Publication number
CA2659477A1
CA2659477A1 CA002659477A CA2659477A CA2659477A1 CA 2659477 A1 CA2659477 A1 CA 2659477A1 CA 002659477 A CA002659477 A CA 002659477A CA 2659477 A CA2659477 A CA 2659477A CA 2659477 A1 CA2659477 A1 CA 2659477A1
Authority
CA
Canada
Prior art keywords
leteprinim
cisplatin
pharmaceutical preparation
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002659477A
Other languages
English (en)
French (fr)
Inventor
Guru Reddy
Dorla Mirejovsky
Luigi Lenaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2659477A1 publication Critical patent/CA2659477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002659477A 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy Abandoned CA2659477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
US60/821,082 2006-08-01
PCT/US2007/075008 WO2008017000A2 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Publications (1)

Publication Number Publication Date
CA2659477A1 true CA2659477A1 (en) 2008-02-07

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002659477A Abandoned CA2659477A1 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Country Status (12)

Country Link
EP (1) EP2046335A2 (enExample)
JP (1) JP2009545619A (enExample)
KR (1) KR20090047501A (enExample)
CN (1) CN101657199A (enExample)
BR (1) BRPI0715504A2 (enExample)
CA (1) CA2659477A1 (enExample)
IL (1) IL196824A0 (enExample)
MX (1) MX2009001116A (enExample)
NO (1) NO20090279L (enExample)
RU (1) RU2009107123A (enExample)
WO (1) WO2008017000A2 (enExample)
ZA (1) ZA200900728B (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
BRPI0715504A2 (pt) 2014-05-06
EP2046335A2 (en) 2009-04-15
IL196824A0 (en) 2009-11-18
RU2009107123A (ru) 2010-09-10
MX2009001116A (es) 2009-02-10
KR20090047501A (ko) 2009-05-12
WO2008017000A3 (en) 2008-03-20
WO2008017000A8 (en) 2009-04-30
ZA200900728B (en) 2010-03-31
CN101657199A (zh) 2010-02-24
NO20090279L (no) 2009-02-26
JP2009545619A (ja) 2009-12-24
WO2008017000A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US20090137619A1 (en) Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
US12310933B2 (en) Treatment of demyelinating disorders
ES2789849T3 (es) Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares
US20090018142A9 (en) Use of phosphatases to treat tumors overexpressing N-CoR
Contreras et al. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice
CA2641308A1 (en) Use of phosphatases to treat tumors overexpressing n-cor
US10117890B2 (en) Methods and compositions for treating pain
Calcutt et al. Protection of sensory function and antihyperalgesic properties of a prosaposin-derived peptide in diabetic rats
Nodera et al. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy
EP3113775A1 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
KR20240013092A (ko) 화학요법-유도된 말초 신경병증과 관련된 통증 치료
Chiorazzi et al. Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models
EP2240177B1 (en) Treatments for neuropathy with xib4035
CN111836622A (zh) 线粒体-氯尼达明、组合物和使用方法
Stengs et al. Cisplatin ototoxicity. An electrophysiological dose-effect study in albino guinea pigs
CA2505937C (en) Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents
CA1248454A (en) Cytidyl diphosphocholine-drug composition and process
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
WO2008017000A2 (en) Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy
AU2011285703B2 (en) Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
EP3019164B1 (en) Use of n-acetylcysteine amide in the treatment of penetrating head injury
KR20230155254A (ko) 프로파페논 및 mTOR 억제제 또는 혈당강하제를 포함하는 암 예방 또는 치료용 약학 조성물
JP2022554230A (ja) 神経系の状態の処置
RU2523792C1 (ru) Лекарственное средство для лечения туберкулеза

Legal Events

Date Code Title Description
FZDE Discontinued